CoChat

PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-methylaminophenyl-6-hydroxybenzathiazole) is under evaluation as a key imaging tool in Alzheimer's disease (AD) and to date has been assumed to bind with high affinity and specificity to the amyloid structures associated with classical plaques (CPs), one of the pathological hallmarks of the disease. However, no studies have systematically investigated PIB binding to human neuropathological brain specimens at the tracer concentrations achieved during in vivo imaging scans. Using a combination of autoradiography and histochemical techniques, we demonstrate that PIB, in addition to binding CPs clearly delineates diffuse plaques and cerebrovascular amyloid angiopathy (CAA). The interaction of PIB with CAA was not fully displaceable and this may be linked to the apolipoprotein E-epsilon4 allele. PIB was also found to label neurofibrillary tangles, although the overall intensity of this binding was markedly lower than that associated with the amyloid-beta (Abeta) pathology. The data provide a molecular explanation for PIB's limited specificity in diagnosing and monitoring disease progression in AD and instead indicate that the ligand is primarily a non-specific marker of Abeta-peptide related cerebral amyloidosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awm191

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Images of adjacent MFG sections from two Category A pathology cases (A1in A^C ; A2 in D^G ), showing correspondence of [3H]-PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Higher power representative images of boxed area from case A2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). Scale bar 1mm.
Fig. 1 Images of adjacent MFG sections from two Category A pathology cases (A1in A^C ; A2 in D^G ), showing correspondence of [3H]-PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Higher power representative images of boxed area from case A2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). Scale bar 1mm.CC-BY-NC · From the PDF
Fig. 2 Images of adjacent SPL sections from two Category B pathology cases (B1in A ^ C ; B2 in D ^ G ), showing correspondence of PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Arrows demonstrate a number of specific corresponding features, including subpial diffuse amyloid deposits (black arrows on left of D and F ). Note that on both sections a considerable number of PIB-labelled areas are not completely displaced by the cold BTA-1 compound and that these additionally coincide with 6E10-labelled foci (black arrows on B). Higher power representative images of boxed area from case B2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). The pink bar and arrows demonstrate corresponding staining of a subpial band of diffuse plaques. Scale bar 1mm.
Fig. 2 Images of adjacent SPL sections from two Category B pathology cases (B1in A ^ C ; B2 in D ^ G ), showing correspondence of PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Arrows demonstrate a number of specific corresponding features, including subpial diffuse amyloid deposits (black arrows on left of D and F ). Note that on both sections a considerable number of PIB-labelled areas are not completely displaced by the cold BTA-1 compound and that these additionally coincide with 6E10-labelled foci (black arrows on B). Higher power representative images of boxed area from case B2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). The pink bar and arrows demonstrate corresponding staining of a subpial band of diffuse plaques. Scale bar 1mm.CC-BY-NC · From the PDF
Image 3
CC-BY-NC · From the PDF
Fig. 3 Images of adjacent OCL sections from two Category C pathology cases (C1 in A ^ C ; C2 in D ^ G ), showing correspondence of PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Note that associated with case C2 ( D ^ F ) the majority of the PIB-labelled areas are not completely displaced by the cold BTA-1 compound and that these additionally coincide with 6E10-labelled foci (black arrows on E and F ). Higher power images of boxed area from case C2 arranged in consecutive cryostat order showing correspondence of PIB binding with 6E10-immunoreactive A b deposits, Thioflavin S-stained amyloid deposits and CAA-NDB ( G ). Blue arrows demonstrate a selection of corresponding amyloidotic blood vessels. Scale bar 1mm.
Fig. 3 Images of adjacent OCL sections from two Category C pathology cases (C1 in A ^ C ; C2 in D ^ G ), showing correspondence of PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Note that associated with case C2 ( D ^ F ) the majority of the PIB-labelled areas are not completely displaced by the cold BTA-1 compound and that these additionally coincide with 6E10-labelled foci (black arrows on E and F ). Higher power images of boxed area from case C2 arranged in consecutive cryostat order showing correspondence of PIB binding with 6E10-immunoreactive A b deposits, Thioflavin S-stained amyloid deposits and CAA-NDB ( G ). Blue arrows demonstrate a selection of corresponding amyloidotic blood vessels. Scale bar 1mm.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 3

  1. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothia- zoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
  2. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52.
  3. Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-12.

Cited by

See all 311

Metadata

Authors
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G.
Affiliations
  • GlaxoSmithKline (United Kingdom) (GB)
  • University Hospital of Basel (CH)
Venue
Brain
Published
2007-10-01
Volume
130
Issue
10
Pages
2607-2615
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2031309116
Cited by
302
References
55
Citations by year
2026: 1 · 2025: 7 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 15 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 13 · 2016: 15 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 35
FWCI
18.76
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Michael J. Fox Foundation for Parkinson's Research (211002, P30 AG19610)
  • GlaxoSmithKline
  • Arizona Department of Health Services (P30 AG19610, 211002, Contract 211002)
  • Arizona Biomedical Research Commission (P30 AG19610, contract 0011, 211002)
  • National Institute on Aging (211002, P30-AG-19610, AG-19610, P30AG019610)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
Keywords
Pittsburgh compound B, [11C]PIB, amyloid-beta, cerebral amyloidosis, Alzheimer's disease, diffuse plaques, neurofibrillary tangles, APOE ε4, autoradiography, amyloid imaging
MeSH terms
Alzheimer Disease, Aniline Compounds, Brain, Carbon Radioisotopes, Humans, Thiazoles, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis. https://app.cochat.ai/papers/10.1093/brain/awm191
The paper
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007). PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis. Brain. https://doi.org/10.1093/brain/awm191

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.